Journal Article10.1200/JCO.1987.5.8.1247
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018).
John M. Kirkwood,Ronald D. Neumann,Sami S. Zoghbi,Marc S. Ernstoff,Eugene A. Cornelius,Coralie Shaw,Toni Ziyadeh,Judith Fine,Michael W. Unger +8 more
35
TL;DR: It is concluded that at doses of greater than or equal to 10 mg, ZME-018 is a safe and potentially useful agent for the scintigraphic detection of metastatic malignant melanoma.
read more
Abstract: We evaluated the toxicity, pharmacokinetics, and localization of a monoclonal IgG2 alpha murine anti-human melanoma (gp240) antibody (ZME-018) that recognizes a tumor-associated cell surface glycoprotein of 240,000 molecular weight present in most melanomas. The antibody was conjugated with DTPA (diethylenetriamine pentaacetic acid) and labeled by chelation of 111In. One mg of antibody labeled with 5 mCi of 111In was infused, together with 0 to 40 mg of "cold" carrier ZME-018. The blood clearance, urinary excretion, and in vivo localization were determined in 26 patients. Scintigraphic images were obtained at 24 hours and 72 hours in all patients. Mild toxicity occurred in one patient. The half-time clearance of labeled monoclonal murine antibody (MoAb) from the blood increased from 16.1 hours at an antibody dose of 1 mg to 35.9 hours at 40 mg. Males showed faster clearance from the blood than did females or a single castrated male, perhaps due to selective concentration of antibody in the testes. Nonspec...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Antibodies as cytotoxic therapy.
TL;DR: There are no unconjugated monoclonal antibodies that have proven therapeutic benefit in hematologic malignancies or solid tumors, but human antimouse antibodies have limited the potential application of murine reagents.
177
•Journal Article
Pharmacokinetics and Tumor Localization of 131I-Labeled Anti-Tenascin Monoclonal Antibody 81C6 in Patients with Gliomas and Other Intracranial Malignancies
TL;DR: These studies demonstrate that the tumor uptake of 131I-labeled 81C6 in patients with gliomas and other intracranial malignancies is due to specific processes.
164
Endometrial cancer
Vicky Makker,Helen MacKay,I. Ray-Coquard,Douglas A. Levine,Shannon N. Westin,Daisuke Aoki,Ana Oaknin +6 more
TL;DR: This comprehensive review provides an update on the epidemiology, pathophysiology, diagnosis and molecular classification, recent advancements in disease management, as well as important patient quality-of-life considerations and emerging developments in the rapidly evolving therapeutic landscape of endometrial cancers.
153
Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody
Jared M. Ashcroft,Dmitri A. Tsyboulski,Keith B. Hartman,Tatiana Y. Zakharian,John W. Marks,R. Bruce Weisman,Michael G. Rosenblum,Lon J. Wilson +7 more
TL;DR: The first fulleren (C60) immunoconjugates have been prepared and characterized as an initial step toward the development of fullerene immunotherapy (FIT).
124
Immunologic and Pharmacologic Concepts of Monoclonal Antibodies
TL;DR: A sound understanding of the pharmacology of presently available native and modified monoclonal antibodies is crucial to better direct their development and application.
74
References
Covalent attachment of chelating groups to macromolecules.
TL;DR: A simple procedure for covalently coupling diethylenetriaminepentaacetic acid to proteins and creates hexadentate chelating sites for metal ions on proteins is described.
391
Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells
TL;DR: Data demonstrate that the antigenic determinant recognized by monoclonal antibody 9.2.27 is located on a glycoprotein-proteoglycan complex which may have unique implications for the interaction of glycoconjugates at the human melanoma tumor cell surface.
346
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms
TL;DR: Immunoprecipitation and sodium dodecyl sulfate gel electrophoresis were used to detect the target antigen in 125I-labeled cell membranes of both cultivated cells and tumor biopsy samples, and a protein with a molecular weight of 97,000 was identified.
281
•Journal Article
Common human melanoma-associated antigen(s) detected by monoclonal antibodies.
TL;DR: Reciprocal binding inhibition tests using [3H]leeucine-labeled antibodies showed that alpha-Mel/5 and alpha- Mel/14 antibodies were directed against different antigenic determinants.
212
•Journal Article
Specific Immunoreactivity of Hybridoma-secreted Monoclonal Anti-Melanoma Antibodies to Cultured Cells and Freshly Derived Human Cells
Meenhard Herlyn,Wallace H. Clark,Michael J. Mastrangelo,DuPont Guerry,David E. Elder,Donato LaRossa,Ralph Hamilton,Edward E. Bondi,Ralph J. Tuthill,Zenon Steplewski,Hilary Koprowski +10 more
TL;DR: Three of the six hybridoma-secreted antibodies bound to the majority of melanoma cell lines, melanoma tumors, and astrocytoma cell Lines as well as to all normal and Epstein-Barr virus-transformed lymphocytes tested.
150